Samaan Rafeq

Johnson & Johnson (United States)

Papers

3

Total Citations

32

H-Index

2

About

Dr. Samaan Rafeq is a leading interventional pulmonologist whose research centers on advancing minimally invasive diagnostic techniques for lung cancer and pulmonary diseases. His most significant contributions lie in the rigorous evaluation of robotic-assisted bronchoscopy, a cutting-edge technology that enhances the precision and safety of lung nodule biopsies. Dr. Rafeq is the principal investigator of the landmark TARGET trial, a prospective, multicenter study that has produced the highest-impact evidence in this field. His seminal 2025 paper, with 27 citations, demonstrated the safety and diagnostic yield of robotic bronchoscopy, establishing new standards for patient care. Earlier reports from the TARGET study, including safety analyses and multicenter outcomes, have further solidified his reputation as a key voice in real-world evidence generation. Through his work, Dr. Rafeq has directly shaped clinical guidelines and provided the data needed for wider adoption of robotic platforms, ultimately improving diagnostic accuracy while reducing procedural risks for patients with suspicious lung lesions.

Research Focus

Key Achievements

2
H-Index
3
Papers
32
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
A Prospective, Multicenter Evaluation of Safety and Diagnostic Outcomes With Robotic-Assisted Bronchoscopy
27 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Johnson & Johnson (United States)

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago